Rituximab for refractory granulomatous eye disease

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 1613-1618

  Lower, Elyse E ^a,b   Baughman, Robert P ^a   Kaufman, Adam H ^c  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b Oncology Hematology Care   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

ANCA; Cyclophosphamide; Sarcoidosis; Wegener's

Indexed keywords

CYCLOPHOSPHAMIDE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; VALACICLOVIR;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISCLERITIS; EYE DISEASE; EYE EDEMA; FEMALE; FOLLOW UP; GRANULOMATOSIS; GRANULOMATOUS EYE DISEASE; HERPETIC STOMATITIS; HUMAN; INFECTION; LEUKOPENIA; LUNG DISEASE; LUNG NODULE; MALE; MOUTH ULCER; NEUTROPENIA; PROGNOSIS; PTOSIS; RECURRENT INFECTION; RELAPSE; RETROSPECTIVE STUDY; REVIEW; SARCOIDOSIS; STAPHYLOCOCCAL SKIN INFECTION; TREATMENT DURATION;

EID: 84867567256     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S35521     Document Type: Review

References (34)

1. DeRemee RA. Sarcoidosis and Wegener's granulomatosis: a comparative analysis. Sarcoidosis. 1994;11:7-18.
2. Ohara K, Judson MA, Baughman RP. Clinical aspects of ocular sarcoidosis. In: Drent M, Costabel U, editors. Sarcoidosis. Wakefield, UK: The Charlesworth Group; 2005:188-209.
3. Baughman RP, Bradley DA, Lower EE. Infliximab for chronic ocular inflammation. Int J Clin Pharmacol Ther. 2005;43:7-11.
4. Kontkanen M, Paimela L, Kaarniranta K. Regression of necrotizing scleritis in Wegener's granulomatosis after infliximab treatment. Acta Ophthalmol. 2010;88:e96-e97.
5. Josselin L, Mahr A, Cohen P, etal. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis. 2008;67:1343-1346.
6. Takeuchi T, Tatsuki Y, Nogami Y, etal. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189-194.
7. Pham T, Claudepierre P, Deprez X, etal. Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Societe Francaise de Rhumatologie, SFR). Joint Bone Spine. 2005;72 Suppl 1:S1-S58.
8. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2006;173:180-187.
9. Stone JH, Merkel PA, Spiera R, etal. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363: 221-232.
10. Belkhou A, Younsi R, El Bouchti I, El Hassani S. Rituximab as a treatment alternative in sarcoidosis. Joint Bone Spine. 2008;75:511-512.
11. Dasilva V, Breuil V, Chevallier P, Euller-Ziegler L. Relapse of severe sarcoidosis with an uncommon peritoneal location after TNF alpha blockade. Efficacy of rituximab, report of a single case. Joint Bone Spine. 2010;77:82-83.
12. Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology. 2010;75:568-570.
13. Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest. 2005;128:1062-1067.
14. Boulter EL, Eleftheriou D, Sebire NJ, Edelsten C, Brogan PA. Inflammatory lesions of the orbit: a single paediatric rheumatology centre experience. Rheumatology (Oxford). 2012;51:1070-1075.
15. Baughman RP, Lower EE, Kaufman AH. Ocular sarcoidosis. Semin Respir Crit Care Med. 2010;31:452-462.
16. Avshovich N, Boulman N, Slobodin G, Zeina AR, Rosner I, Rozenbaum M. Refractory Wegener's granulomatosis: effect of rituximab on granulomatous bilateral orbital involvement. Isr Med Assoc J. 2009;11:566-568.
17. Martinez Del Pero M, Chaudhry A, Jones RB, Sivasothy P, Jani P, Jayne D. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol. 2009;34:328-335.
18. Ooka S, Maeda A, Ito H, Omata M, Yamada H, Ozaki S. Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener's granulomatosis: a case report. Mod Rheumatol. 2009;19:80-83.
19. Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum. 2009;60:1540-1547.
20. Joshi L, Lightman SL, Salama AD, Shirodkar AL, Pusey CD, Taylor SR. Rituximab in refractory ophthalmic Wegener's granulomatosis: PR3 titers may predict relapse, but repeat treatment can be effective. Ophthalmology. 2011;118:2498-2503.
21. Cheung CM, Murray PI, Savage CO. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol. 2005;89:1542.
22. Henes JC, Fritz J, Koch S, etal. Rituximab for treatment-resistant extensive Wegener's granulomatosis-additive effects of a maintenance treatment with leflunomide. Clin Rheumatol. 2007;26:1711-1715.
23. Jones RB, Tervaert JW, Hauser T, etal. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211-220.
24. Lower EE, Blau R, Gazder P, Tummala R. The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med. 1999;8:949-954.
25. Talar-Williams C, Hijazi YM, Walther MM, etal. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996;124:477-484.
26. Aksoy S, Dizdar O, Hayran M, Harputluoglu H. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk Lymphoma. 2009;50:357-365.
27. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68:25-32.
28. Lanini S, Molloy AC, Fine PE, Prentice AG, Ippolito G, Kibbler CC. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med. 2011;9:36.
29. Tesfa D, Ajeganova S, Hagglund H, etal. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63:2209-2214.
30. Lower EE, Smith JT, Martelo OJ, Baughman RP. The anemia of sarcoidosis. Sarcoidosis. 1988;5:51-55.
31. Browne PM, Sharma OP, Salkin D. Bone marrow sarcoidosis. JAMA. 1978;240:43-50.
32. Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford). 2007;46:626-630.
33. Cabanillas F, Liboy I, Pavia O, Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol. 2006;17:1424-1427.
34. Treon SP, Ioakimidis L, Soumerai JD, etal. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27:3830-3835.